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Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as serum platelet activating
factor acetylhydrolase (PAF-AH) activity constitutes a novel risk marker for cardiovascular disease.
Leukocytes constitute one main cellular source of circulating Lp-PLA2. The aim of the present study was
to evaluate the association of both serum and leukocyte PAF-AH activities with fat distribution and lean
tissue. One hundred healthy volunteers without cardiovascular disease history participated in this study
(n = 52 men, 44 ± 13 years and n = 48 women, 43 ± 13 years). Body composition was assessed with dual-
energy X-ray absorptiometry, while anthropometrical indices were also measured. The activity of Lp-PLA2
and levels of lipid and glycemic parameters were determined in fasting samples.
Results:  Mean Lp-PLA2 activity was 24.8 ± 4.5 and 19.6 ± 5.0 nmol/min/mL in men and women,
respectively (P < 0.001). Mean activity of PAF-AH in leukocyte homogenates was 386 ± 127 pmol/min/mg
and 292 ± 92 pmol/min/mg in men and women, correspondingly (P < 0.001). In multiple regression models
upper and total adiposity measures were positively associated with Lp-PLA2 activity in men after adjusting
for LDL-cholesterol, age, smoking, hs-CRP and physical activity, whereas no associations were found with
PAF-AH leukocyte homogenates activity. Hierarchical analysis revealed that the variables with the highest
explanatory ability of Lp-PLA2 activity in men, were DXA deriving L1–L4 region of interest and arms fat
(increase in R2 = 0.136, P = 0.005 and increase in R2 = 0.118, P = 0.009, respectively), followed by trunk
fat and total fat. In women, no association of body composition variables with Lp-PLA2 nor PAF-AH
leukocyte homogenates activity was found.
Conclusion: Lp-PLA2 activity is differentiated across levels of adiposity and topology of adipose tissue,
whereas no association was found regarding PAF-AH leukocyte homogenates activity. Our findings suggest
that Lp-PLA2 may compensate for the adiposity-associated increases in inflammatory and oxidative burden,
in men.
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Background
Adipose tissue has been well recognised as an endocrine
organ as it secretes several molecules with endocrine,
paracrine and autocrine actions. Moreover, its accumula-
tion at the upper body compartments results in the infil-
tration of macrophages [1] and the concomitant
production of pro-inflammatory, pro-oxidant and pro-
thrombotic factors, such as tumor-necrosis factor alpha
(TNF-α), interleukin-6 (IL-6), platelet activating factor
(PAF), PAF-like molecules and oxidized phospholipids
[2-4]. This local inflammatory burst characterized with tis-
sue remodelling, macrophage activation and enhanced
chemoattraction of leukocytes together with the predom-
inance of a systemic low grade inflammatory state turn the
adipose tissue into a key player in atherosclerosis progress
and inflammation [5]. On the other hand, lean tissue has
been found to be inversely related to inflammatory indi-
ces [6].
Lipoprotein associated phospholipase A2 (Lp-PLA2), also
known as plasma platelet activating factor acetylhydrolase
(PAF-AH), is a Ca2+-independent enzyme implicated in
inflammation and atherosclerosis [7]. It is mostly bound
to LDL particles and in a lesser extent to HDL and VLDL
lipoproteins and it is mainly produced by monocytes,
macrophages, platelets and mast cells [7]. An accumulat-
ing body of evidence supports that Lp-PLA2 is a novel risk
marker for cardiovascular disease [8]. As far as its action is
concerned, it cleaves short chain acyl chains at the sn-2
position of phospholipids [7] such as, oxidized phosphol-
ipids and PAF [9], which is strongly implicated in athero-
sclerosis and inflammation [10]. From this point of view,
Lp-PLA2 could be characterized as an anti-atherogenic
enzyme. However, its action goes hand in hand with the
production of inflammatory molecules, such as lyso-
phosphatidylcholine and oxidized non esterified fatty
acids [7], which are proatherogenic.
According to recent observations, adiposity may be impli-
cated in the regulation of Lp-PLA2 activity together with
age, gender and LDL-cholesterol [11,12], although not all
studies agree [3]. This field has become even more com-
plicated since epidemiological studies are inconsistent as
far as the relation of body mass index (BMI) with Lp-
PLA2is concerned [12-19]. No study, so far, has investi-
gated the association of both central and peripheral fat, as
well as lean tissue with Lp-PLA2, despite the urgent need
for an in-depth analysis of Lp-PLA2 determinants. The
present work aimed at evaluating the relation of Lp-PLA2
activity in serum and the enzyme activity in leukocytes
(PAF-AH in leukocytes), a major cellular source of the cir-
culating enzyme, with body composition as assessed with
dual X-ray absorptiometry (DXA) in healthy adults.
Methods
Subjects
Fifty two (52) men and forty eight (48) age- and BMI-
matched women (15 menopausal) from the Athens
greater area, were studied in our Institution. Exclusion cri-
teria were medical treatment, history of cardiovascular or
any other inflammatory disease, cold or flu, acute respira-
tory infection, dental problems and renal/hepatic abnor-
malities.
Bioethics
The protocol was approved by the Bioethics Committee of
Harokopio University and was in accordance with the
Declaration of Helsinki (1989) of the World Medical
Association and all participants gave their informed writ-
ten consent in order to participate in the study.
Lifestyle variables assessment
Smokers were classified as current smokers (smoking
daily at least one cigarette per day), former smokers and
never smokers. Physical activity was assessed with the use
of a validated questionnaire (IPAQ-short version) and
was expressed in metabolic equivalents minutes per week
(MET-min-week) [20].
Anthropometric measurements
Weight and height were measured in light clothing and
without shoes. BMI was then calculated as weight (kg)
divided by height2 (m2). Waist circumference was meas-
ured between the superior iliac crest and the lower rib
margin in the midaxillary line and hip circumference as
the maximal horizontal circumference at the level of the
buttocks. Both circumferences were measured to the near-
est 0.1 cm and waist to hip ratio was calculated. Sagittal
diameter was measured with an anthropometer (Lafayette
Instr.) as previously suggested [21]. The abdominal skin-
fold was measured 3 cm lateral and 1 cm inferior to the
midpoint of the umbilicus with a Harpenden caliper
(Harpenden, UK) in triplicate to the nearest 0.1 mm. All
measures were performed at the right side of the body by
the same individual.
DXA measurements
Body composition was assessed by DXA (Lunar, Corpora-
tion, Brussels, Belgium) set at medium speed and accord-
ing to the manufacturer's instructions. Prior to the
scanning procedure, subjects were asked to remove all
materials that could attenuate the X-ray beam. Besides the
standard body composition analysis (software version
4.6), for each subject a "region of interest" (ROI) was
manually defined as a quadrilateral box around the L1–L4
area as previously described [22]. The fat in this ROI is
strongly correlated with visceral adipose tissue as deter-
mined from CT scans (gold standard method) [22] and is
a more informative measure of central adiposity thanLipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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trunk fat in women especially, given that trunk fat in
females includes the sex-specific (i.e. breast) fat. To elimi-
nate the between examiners errors all the analysis were
performed by the same individual.
Isolation of leukocytes from heparinized blood
Five mL of heparinized blood were obtained from each
volunteer. In order to induce erythrocyte sedimentation,
1.7 mL of dextran solution (3% dextran in NaCl 0.15 M)
was added and the mixture was kept for 1 h at room tem-
perature. The leukocyte rich supernatant was then centri-
fuged at 500 × g for 10 min at room temperature.
Contaminating erythrocytes of the sediment were lysed
with the addition of a lysis solution consisting of 155 mM
NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA and then
removed with a centrifugation at 300 × g for 10 min at
room temperature. The pelleted cells were resuspended in
1 mL of a buffer containing 50 mM Tris-HCl (pH 7.4),
0.25 M sucrose and 1 mM DTT and then sonicated on ice
for 4 times of 10 sec each. The leukocyte homogenate was
aliquoted and stored at -80°C. Protein concentrations of
all preparations, were determined according to the Brad-
ford method [23] with the use of BSA as protein standard.
Biochemical measurements
PAF-AH and Lp-PLA2 activities in leukocyte homogenates
and serum respectively were determined by the trichloro-
acetic acid precipitation method using [3H] PAF as a sub-
strate. Briefly, leukocyte homogenates (containing 60 μg
of total protein) or 2 μL of serum were incubated with 4
nmol of [3H] PAF (20 Bq per nmol) for 15 min, at 37°C
in a final volume of 200 μL of 100 mM Tris/HCl buffer
(pH 7.2) containing 1 mM EGTA. The reaction was termi-
nated by the addition of cold trichloroacetic acid (10%
final concentration). The samples were then placed in an
ice bath for 30 min and subsequently centrifuged for 2
min at 14000 g. The [3H]-acetate released into the aque-
ous phase was measured on a liquid scintillation counter.
All assays were performed in duplicate. The enzyme activ-
ity was expressed as nmol of PAF degraded per min per mg
of leukocyte homogenate protein or per mL of serum.
Serum glucose, triacylglycerols, total cholesterol and HDL
cholesterol were determined enzymatically in fasting sam-
ples (ACE analyzer, Schiapparelli Biosystems, Inc, New
Jersey, USA) using reagents from Alfa Wassermann (Woer-
den, The Netherlands). LDL was calculated with the
Friedewald Formula. High sensitivity C-reactive protein
was measured in a LISA 200 analyser (Biocode, Hycel)
using commercially available reagents (Siemens Health-
care Diagnostics).
Statistical analysis
Normally distributed continuous variables are presented
as mean values ± standard deviation, while skewed varia-
bles as median and quartiles. Categorical variables are
presented as relative frequencies (%). For the compari-
sons between genders the independent samples t-test for
normally distributed variables or the Mann-Whitney of
the skewed and the chi-square test for categorical varia-
bles, were used. Correlations were evaluated using the
Pearson coefficient for the normally distributed and the
Spearman for the skewed variables. Regression models
were applied in order to evaluate the effect of adiposity
measures (as explanatory variables) on Lp-PLA2 activity or
PAF-AH activity in leukocytes (as dependent outcomes),
after adjustment for LDL-cholesterol, age, smoking and
physical activity (covariates), which are known to deter-
mine Lp-PLA2 activity [12-15,24]. Moreover, smoking and
physical activity were also included in the models as they
are related to Lp-PLA2 activity through the oxidative mod-
ification of LDL-particles [25]. In order to test whether the
relations of Lp-PLA2 activity with body fat compartments
are influenced by inflammatory state, C-reactive protein
was also entered in the regression models. Normality of
the residuals of the regression analyses was tested through
P-P plots and the Kolmogorov-Smirnoff criterion, while
the assumptions of non co-linearity, homoscedacity and
independency were tested using the scatter plots of pre-
dicted against standardised residuals and the calculation
of the Variance Inflation Factor. Results from regression
models are presented as b-coefficients and standard error.
In order to "hierarchy" the explanatory ability of adiposity
variables on Lp-PLA2 activity, additive regression models
were applied with age, LDL-cholesterol, smoking and
physical activity as the core model and each adiposity
measure as the additive variable. The change in R-squared
values (i.e. the coefficient of determination, which repre-
sents the proportion of variability in the data that is
accounted for by the regression model) was calculated
and the corresponding F-test assisted in order to evaluate
significance.
We have also assessed the relation of Lp-PLA2 activity and
PAF-AH in leukocytes with patterns of adipose and lean
tissue measures with a multivariate technique, the Princi-
pal Component Analysis (PCA). In this way, after evaluat-
ing the correlations between continuous variables, new
variables were created which "summarize" the existing
information. To decide the number of components to
retain from the PCA, the eigenvalues that derived from the
correlation matrix of the standardized variables were
examined (the eigenvalue evaluates the proportion of the
variance in consumption explained by each extracted
component). According to the Kaiser criterion, the
number of components that should be retained is equal to
the number of eigenvalues that are greater than one. Based
on the principle that the component scores are interpreted
similarly to correlation coefficients (thus, higher absolute
values indicate that the body composition variable con-Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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tributes most to the formulation of a component), the
body composition patterns were defined in relation to
scores of the body composition variables that correlated
most with the factor (scores >0.5 were used). The orthog-
onal rotation with varimax option was used to derive opti-
mal, non-correlated body composition components (i.e.
body composition patterns). The information was rotated
in order to increase the representation of each body com-
position to a component. All reported P-values were
based on two-sided tests and compared to a significance
level of 5%. SPSS 14 (SPSS Inc., Chicago, Illinois, USA)
software was used for statistical analysis.
Results
Mean Lp-PLA2 activity was 24.8 ± 4.5 nmol/min/mL in
men and 19.6 ± 5.0 nmol/min/mL in women (P < 0.001)
(range 15.7–37.8 and 11.0–37.1 nmol/min/mL in men
and women, respectively). Mean activity of PAF-AH in
leukocyte homogenates was 386 ± 127 pmol/min/mg in
men (ranging from 142 to 714 pmol/min/mg) and 292 ±
92 pmol/min/mg in women (ranging from 96 to 545
pmol/min/mg), correspondingly (P < 0.001). Table 1
demonstrates the basic anthropometric and clinical char-
acteristics of participants. There was no significant differ-
ence between men and women regarding age, BMI and
smoking habits, whereas differences in certain biochemi-
cal parameters and body composition measurements,
such as total body fat and central adiposity were observed.
Moreover, positive correlations were documented
between Lp-PLA2activity and total- (r = 0.588, P < 0.001 in
men and r = 0.645, P < 0.001 in women), LDL-cholesterol
(r = 0.531, P < 0.001 in men and r = 0.574 and P < 0.001
in women) and triglycerides (log-values) (r = 0.504, P <
0.001 in men and r = 0.352, P = 0.012 in women) (data
not shown). PAF-AH in leukocyte homogenates was asso-
ciated with LDL-cholesterol and Lp-PLA2 in women (r =
0.338, p = 0.013 and r = 0.278, p = 0.049), whereas in
men no association was found between PAF-AH in leuko-
cyte homogenates with lipid parameters or Lp-PLA2 activ-
ity (data not shown). Interestingly, PAF-AH in leukocyte
homogenates was associated with CRP levels (r = 0.338, p
= 0.023 and r = 0.316, p = 0.019 in men and women,
respectively) whereas the activity of Lp-PLA2 showed no
similar trend (data not shown).
In Table 2 the unadjusted Pearson correlation coefficients
between Lp-PLA2 activity, PAF-AH in leukocyte homoge-
nates and various body composition variables are dis-
Table 1: Selected biochemical and anthropometric characteristics of the subjects.
Men (n = 52) Women (n = 48) P
Mean or Median† SD or quartiles Mean or Median SD or quartiles
Age (years) 43.7 13.3 42.8 12.8 0.726a
Body mass Index (kg/m2) 27.4 3.8 25.7 5.6 0.087a
Current smokers (%) 34.7 27.6 0.640b
MET (minutes per week) 1043 1046 951 954 0.658a
Lp-PLA2 activity (nmol/min/mL) 24.8 4.5 19.6 5.0 <0.05a
PAF-AH activity in leukocyte homogenates 
(pmol/min/mg)
386 127 292 92 <0.05a
Glucose (mmol/L) 5.22 0.43 5.02 0.72 0.101a
Triglycerides (mmol/L) 1.34 0.89–1.71 0.75 0.56–1.04 <0.05a
Total cholesterol (mmol/L) 5.66 0.97 5.47 1.20 0.396a
HDL-cholesterol (mmol/L) 1.10 0.20 1.28 0.31 <0.05a
LDL-cholestrerol (mmol/L) 3.89 0.78 3.74 1.02 0.401a
C-reactive protein (mg/dL) 0.40 0.34–0.49 0.39 0.31–0.48 0.438a
Waist circumference (cm) 92.8 9.2 77.7 16.1 <0.05a
Hip circumference (cm) 104.7 7.0 103.8 15.7 0.696a
Waist- to- hip ratio 0.9 0.1 0.7 0.1 <0.05a
Sagittal diameter (cm) 23.4 3.4 20.1 4.5 <0.05a
Abdominal skinfold (mm) 28.3 7.2 27.4 10.0 0.612a
% Total body fat 26.7 5.2 37.2 8.4 <0.05a
DXA ROI fat (kg) 3.0 0.9 2.7 1.5 0.116a
Legs fat (kg) 6.8 3.0 9.2 3.9 <0.05a
Arms lean tissue (kg) 3.81 0.60 6.67 1.18 <0.05a
Legs lean tissue (kg) 12.45 1.95 18.78 2.85 <0.05a
MET: Metabolic equivalent, ROI: Region of interest, DXA: dual energy X-ray absorptiometry
† Data are presented as mean ± standard deviation for normally distributed variables. Otherwise data are presented as median ± lower (Q0.25) and 
upper (Q0.75) quartile.
a Student t-test was used to compare means.
b Chi-square test was used to compare percentages in the two groups.Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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played. Data are presented separately in men and women
since a significant interaction was observed between
anthropometry or body composition variables and gender
on the investigated outcome (P < 0.05). Associations of
adiposity parameters with Lp-PLA2 and PAF-AH in leuko-
cyte homogenates were more prominent in men. Particu-
larly, Lp-PLA2 activity was positively associated with trunk
fat, DXA ROI fat, arms fat and total fat and marginally
associated with waist circumference (P = 0.10) in men,
whereas in women no association was detected between
the enzyme activity and body fat compartments. PAF-AH
in leukocytes homogenates displayed a similar pattern,
since it was positively associated with DXA ROI fat and %
total body fat in men, whereas in women no association
with body fat indices was observed. Legs lean mass was
inversely related to the activity of both Lp-PLA2 and PAF-
AH in leukocytes activities in women, whereas an inverse
association of arms lean mass with PAF-AH activity in leu-
kocytes was observed in men.
In Table 3 the associations of anthropometry and body
composition variables with Lp-PLA2 activity are displayed,
after adjusting for LDL-cholesterol, age, smoking, hs-CRP
and physical activity. Fat in the DXA ROI, arms fat, trunk
fat and total body fat were positively associated with Lp-
PLA2 activity in men, while no associations were found in
women. Lean tissue in arms and legs were also included in
similar regression models but were not significant predic-
tors of Lp-PLA2 activity. A posterior  observed power for
these non significant associations in women was about
45%. For this reason more emphasis will be given to the
observed relations in men throughout this work. The asso-
ciations of PAF-AH activity in leukocytes with body fat
and lean tissue indices were not significant in age adjusted
multiple regression models and fully adjusted multiple
regression models (data not shown), in which PAF-AH
activity in leukocyte homogenates was used as a depend-
ent variable.
Table 4 presents R-squared values, the corresponding F-
tests and p-values in various additive models that evalu-
ated the explanatory ability of body composition parame-
ters on Lp-PLA2  activity. It is noteworthy that LDL-
cholesterol, age, smoking and physical activity when
regarded as a variables block explained approximately
30% of the variability of the enzymatic activity, which is
in line with the results of other studies [12]. Although
there were no significant differences between consecutive
Table 2: Pearson correlation coefficients of Lp-PLA2 and leukocyte PAF-AH activities with body composition indices in men and 
women.
Serum Lp-PLA2 activity PAF-AH activity in leukocytes homogenate
Men
(n = 52)
Women (n = 48) Men
(n = 52)
Women
(n = 48)
Body mass index (BMI) (kg/m2)0 . 2 0 6
(P = 0.170)
-0.051
(P = 0.718)
0.163
(P = 0.284)
-0.044
(P = 0.746)
Waist circumference (cm) 0.240
(P = 0.100)
-0.005
(P = 0.975)
0.146
(P = 0.327)
-0.218
(P = 0.114)
Hip Circumference (cm) 0.202
(P = 0.168)
-0.043
(P = 0.766)
0.070
(P = 0.639)
-0.037
(P = 0.791)
Sagittal diameter (cm) 0.173
(P = 0.252)
0.007
(P = 0.963)
0.178
(P = 0.243)
0.088
(P = 0.532)
Abdominal skinfold (mm) 0.170
(P = 0.253)
0.086
(P = 0.554)
0.022
(P = 0.883)
0.087
(P = 0.531)
DXA ROI fat (kg) 0.380
(P = 0.008)
-0.088
(P = 0.535)
0.247
(P = 0.094)
-0.020
(P = 0.883)
Trunk fat (kg) 0.356
(P = 0.013)
-0.063
(P = 0.663)
0.162
(P = 0.277)
-0.040
(P = 0.772)
Arms fat (kg) 0.318
(P = 0.028)
0.083
(P = 0.563)
0.097
(P = 0.518)
-0.186
(P = 0.174)
Legs fat (kg) 0.084
(P = 0.572)
-0.099
(P = 0.488)
0.149
(P = 0.316)
-0.132
(P = 0.338)
% total body fat 0.229
(P = 0.118)
0.006
(P = 0.967)
0.296
(P = 0.044)
-0.071
(P = 0.608)
Total body fat (kg) 0.253
(P = 0.083)
-0.064
(P = 0.657)
0.167
(P = 0.263)
-0.098
(P = 0.475)
Arms lean tissue (kg) 0.004
(P = 0.979)
-0.093
(P = 0.518)
-0.333
(P = 0.022)
-0.152
(P = 0.266)
Legs lean tissue (kg) 0.058
(P = 0.698)
-0.318
(P = 0.023)
-0.222
(P = 0.133)
-0.219
(P = 0.100)
P values are shown in parenthesis. All variables were normally distributed according to Kolmogorov Smirnoff Kriterion.Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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R2 values, the hierarchy of anthropometric indices is of
importance in clinical settings. The variable with the high-
est significant additive explanatory ability on top of back-
ground confounding was fat in the DXA ROI (i.e. R2
change = 0.136, P = 0.005), followed by arms fat, trunk fat
and total body fat (Table 4).
Given that lean tissue has been found to be inversely
related to inflammatory markers and strong correlations
exist between adiposity and lean tissue measures, we eval-
uated the relation of Lp-PLA2 activity and PAF-AH in leu-
kocytes with patterns of adipose and lean tissue measures
with the technique of PCA. In the PCA analysis two com-
ponents of body composition were extracted in men and
women, i.e. the "fatness" (that was loaded by total body
fat, DXA ROI fat, arms fat and legs fat) and the "leanness"
(total lean tissue, legs lean tissue and arms lean tissue)
(Table 5). These components were then entered in the
multiple adjusted regression models, in order to evaluate
the effects of fat and lean tissue on Lp-PLA2 activity and
PAF-AH activity in leukocyte homogenates. In men, the
fatness component was a significant predictor of Lp-PLA2
activity in multi-adjusted analysis, whereas in age
adjusted regression models it was not a significant predic-
tor of PAF-AH activity in leukocyte homogenates. In
women, neither the fatness component nor the leanness
component showed any association with the measured
enzymatic activities (Table 6).
Table 3: Multi-adjusted linear regression models with Lp-PLA2 as dependent variable.
Men (n = 52) Women (n = 48)
BS EP BS E P
Model 1
LDL-cholesterol (mmol/L) 3.140 0.869 0.001 4.084 0.632 <0.001
Age (years) -0.077 0.053 0.156 -0.078 0.051 0.137
Smoking (never/former vs. current smoker) -0.570 1.324 0.669 1.067 1.145 0.357
MET minutes per week (× 100) 0.002 0.001 0.768 0.000 0.001 0.640
hs C-reactive protein (mg/dL) 3.891 2.623 0.147 -1.166 2.470 0.640
Model 1 + one variable of the following:
Body mass index (kg/m2) 0.227 0.161 0.168 -0.021 0.121 0.860
Waist circumference (cm) 0.097 0.068 0.160 0.022 0.038 0.565
Hip circumference (cm) 0.161 0.082 0.057 0.019 0.034 0.579
Waist-to-hip ratio 1.753 11.422 0.879 1.084 4.158 0.796
Sagittal diameter (cm) 0.267 0.197 0.184 -0.039 0.139 0.784
Abdominal skinfold (mm) 0.132 0.092 0.161 0.022 0.061 0.720
DXA ROI fat (kg) 1.867 0.620 0.005 -0.270 0.447 0.549
Trunk fat (kg) 0.409 0.151 0.010 -0.068 0.111 0.546
Arms fat (kg) 2.313 0.835 0.009 0.195 0.568 0.734
Legs fat (kg) 0.299 0.197 0.138 -0.042 0.447 0.776
% total body fat 0.218 0.106 0.046 -0.045 0.076 0.647
Total body fat (kg) 0.178 0.078 0.029 -0.023 0.557 0.690
MET: Metabolic equivalent; ROI: region of interest; DXA: dual energy X-ray absorptiometry.
All models are also adjusted for LDL-cholesterol, age, smoking and physical activity.
Table 4: R-squared values, and corresponding F-tests in various models that evaluated the explanatory ability of body composition 
parameters towards Lp-PLA2 activity.
Initial model: R2 F P
LDL-cholesterol, age, smoking, physical activity 0.296 4.098 0.007
Additive models (initial + one of the following variables): R2 change* F P
DXA ROI fat 0.136 9.076 0.005
Arms fat 0.118 7.678 0.009
Trunk fat 0.114 7.316 0.010
Total body fat 0.084 5.152 0.029
ROI: Region of interest; DXA: dual energy X-ray absorptiometry.
The other anthropometric variables tested did not have a significant additive explanatory effect on Lp-PLA2 activity.
* The change in R-squared values between the additive and the initial models.Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
Page 7 of 10
(page number not for citation purposes)
Discussion
This is the first study evaluating the relation of Lp-PLA2
activity and PAF-AH activity in leukocytes to fat distribu-
tion in healthy adults. Main findings indicate that meas-
ures of upper adiposity (i.e. fat in the DXA ROI and arms
fat) had the highest explanatory ability of Lp-PLA2 activity
among other indices of adiposity in men in multi-
adjusted models, whereas adiposity was not a significant
determinant of PAF-AH activity in leukocyte homoge-
nates.
Our results should be viewed taking into consideration
existing studies, in which BMI and/or classic anthropo-
metric indices were measured. In particular, weight loss
has been found to induce reductions in Lp-PLA2activity in
obese women [11]. Patients with the metabolic syn-
drome, which are characterized with central adiposity dis-
play higher levels of Lp-PLA2  [26,27], while Lp-PLA2
concentration has been positively correlated with meas-
ures of central adiposity in obese children [28] and in
adults [29]. Epidemiological studies tend to show no rela-
tion of adiposity to Lp-PLA2 with some exceptions [12-
19]. These discrepancies could be attributed to the inher-
ent weaknesses of BMI as an index of adiposity [30] as it
does not reflect fat distribution nor distinguishes between
lean and fat mass.
In this context, the DXA-based body composition analysis
performed in our study is informative as far as adipose
and lean tissue compartmentalization is concerned. The
magnitude of the additive explanatory ability of arms and
trunk adiposity for Lp-PLA2 activity was approximately
10% after adjustments for the effects of classic confound-
ers, such as LDL-cholesterol, smoking, hs-CRP levels, age
and physical activity. This contradicts the generally
believed view that Lp-PLA2 is minimally correlated with
risk factors other than age, gender and LDL-cholesterol
[13]. We believe that in male participants arm adiposity
represents an upper fat distribution and reflects the effects
of trunk adiposity on Lp-PLA2. This was also shown from
the PCA analysis, in which subjects displaying the "fatness
pattern" had increased values for all body fat compart-
ments. Leg fat was not shown to have any protective effect
against Lp-PLA2 possibly because of the fact that male par-
ticipants accumulated fat mainly in the central area. This
relation of Lp-PLA2 to upper fat depots can be better
understood in the light of visceral adipose tissue meta-
bolic effects given that DXA L1–L4 ROI fat and trunk adi-
posity are strongly correlated with visceral adipose tissue
Table 5: Score coefficients derived from principal components analysis regarding body composition variables and identification of body 
composition patterns for male and female participants.
Men Women
Component 1:
Fatness
Component 2:
Leanness
Component 1:
Fatness
Component 2:
Leanness
DXA ROI fat 0.915 -0.142 0.937 0.118
Arms fat 0.948 0.093 0.946 0.152
Legs fat 0.897 0.208 0.909 0.290
Total fat 0.990 0.088 0.968 0.217
Arms lean -0.095 0.946 0168 0.893
Legs lean 0.230 0.926 0.187 0.902
Score coefficients are similar to the correlation coefficients. Higher absolute values indicate that the body composition variable is correlated with 
the respective component. Numbers in bold indicate loadings greater than 0.5.
Table 6: Multiple linear regression models with Lp-PLA2 or PAF-AH in leukocytes homogenates as dependent variable and PCA 
component scores as independent variables.
†Lp-PLA2 ‡PAF-AH in leukocyte homogenates
Men (n = 52) Women (n = 48) Men (n = 52) Women (n = 48)
b ± SE P b ± SE P b ± SE P b ± SE P
"Fatness" scores 1.43 ± 0.58 0.019 -0.40 ± 0.66 0.548 25.98 ± 20.31 0.209 4.61 ± 16.42 0.780
"Leaness" scores 0.05 ± 0.75 0.946 0.24 ± 0.56 0.673 -35.62 ± 28.55 0.193 -21.06 ± 13.29 0.120
† All models were adjusted for age, smoking habits, physical activity (METs per week) and LDL-cholesterol
‡ All models were adjusted for age, smoking habits and physical activity (METs per week).Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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as determined from CT scans [22]. Indeed, lipolytic stim-
uli of visceral fat can lead to increases in free fatty acids
which are connected to oxidative stress [31] and possibly
implicated along with Lp-PLA2 in the atherosclerosis proc-
ess [32]. Moreover, visceral fat has been positively related
to small dense LDL particles, in which Lp-PLA2 is preferen-
tially bound [33]. It is noteworthy that in a recent publi-
cation from the Framingham Heart Study no correlation
of Lp-PLA2 activity nor mass was detected with visceral fat
[3], whereas preliminary results from the HERITAGE
study indicated a positive association of Lp-PLA2 activity
with visceral fat [34]. For the interpretation of the above
conflicting results, it should be noted that the Framing-
ham Heart study participants were old (mean age 60
years) and medically treated (30% of the participants were
chronic aspirin users) [3], whereas in the present study the
participants were much younger, healthy and not medi-
cally treated.
The relation of adiposity to Lp-PLA2 observed in our study
may be explained through the pleiotropic molecules
being secreted by adipocytes, such as TNF-α, which may
induce Lp-PLA2 secretion from various cells [35]. In addi-
tion, we should notice that an increase in Lp-PLA2 can also
be mediated by an increase in PAF and oxidized phos-
pholipids levels, resulting from the adipose tissue inflam-
matory burst, in order to degrade these bioactive
molecules. The inclusion of hs-CRP in regression models
did not attenuate the magnitude of the documented rela-
tionship between Lp-PLA2 activity and adiposity indices.
This finding is in line with evidence suggesting that Lp-
PLA2 is not associated in the present and other studies
with CRP [12,13,36], although some studies report an
association of CRP and Lp-PLA2 [15], and lends evidence
to the fact that that more specific mediators of inflamma-
tion (e.g. TNF-α) may potentiate the increases in Lp-PLA2
in cases of fat accumulation. Moreover, adipocytes can
also secrete PAF and have detectable amounts of PAF-AH
[4,37] and may thus contribute in circulating levels of Lp-
PLA2, although its main cellular source are macrophages
[7]. Adipose-tissue deriving hormones, such as leptin,
which is increased in obesity, may provide an additional
mechanism through which adipose tissue may influence
Lp-PLA2activity [18]. A leptin mediated upregulation of
Lp-PLA2, however, most probably does not explain the
relations documented in the present study, given that lep-
tin was not correlated with Lp-PLA2 in men (r = 0.189, P =
0.309) (data not presented).
As far as PAF-AH activity in leukocyte homogenates is con-
cerned, it was positively correlated with measures of adi-
posity in males and negatively associated with lean tissue
in males and females but these associations were not sig-
nificant in age- and multi-adjusted models. The differen-
tiated nature of adiposity related regulation of PAF-AH
activity in leukocyte homogenates and Lp-PLA2 activity in
the volunteers studied may be explained by the inherent
differences of the enzymatic activities measured. Firstly,
although leukocytes constitute a source of Lp-PLA2 activity
other cells can also produce and secrete Lp-PLA2, such as
platelets, adipocytes, macrophages resident in adipose tis-
sue etc. [7,37]. Indeed, in the present study platelet count
was significantly correlated with Lp-PLA2 activity in men
(r = 0.318, p = 0.031). Moreover, the production of Lp-
PLA2 from leukocytes may be higher in pathological con-
ditions, in which these cells are stimulated [35] compared
to a relatively steady state in healthy volunteers included
in the present study. Secondly, leukocytes contain not
only the serum type Lp-PLA2 but also the intracellular type
I PAF-AH [38], which are both measured in the assay used.
However, the relative contribution of the type I PAF-AH in
the activity measured is negligible [38]. Thirdly, the possi-
ble differences in the regulation of enzymatic activities
measured are reflected to the different patterns of associa-
tions with inflammatory indices documented in this and
other studies [36].
Limitations of our study include its cross-sectional nature,
which can only generate hypothesis and not provide
causal explanations. Lack of visceral fat mass data (by CT
or MRI) is another limitation in the current study. How-
ever, it is probable that the observed relations between
upper fat depots and Lp-PLA2 reflect the effects of visceral
compartments since no relation was detected with central
measures of subcutaneous fat (i.e. abdominal skinfold
thickness) and Lp-PLA2. Moreover, the presented results
for women concern both pre- and post- menopausal
women. Separate analysis was difficult given the small
number of female volunteers in each subgroup. Last but
not least, it should be noted that in the present study total
Lp-PLA2 activity was measured although LDL- and HDL-
associated Lp-PLA2 activity determinations could be more
informative in the light of the apparently different actions
of Lp-PLA2 attached to these subfractions. However, the
given results would not be significantly differentiated if
HDL-associated activity was included, since as Tellis et al
discuss the HDL-associated Lp-PLA2 activity represents
about 5% of the total plasma enzyme activity, and does
not considerably contribute to the total plasma enzyme
activity [7].
Conclusion
In conclusion, this is the first study to substantiate a dif-
ferentiation in Lp-PLA2 activity across upper adiposity lev-
els in healthy men, whereas PAF-AH activity in leukocytes
was not related to measures of adiposity nor lean tissue in
the subjects studied. Our innovative findings suggest that
Lp-PLA2 activity may increase in order to compensate for
the adiposity-associated increases in inflammatory and
oxidative burden.Lipids in Health and Disease 2009, 8:19 http://www.lipidworld.com/content/8/1/19
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